Jim W Hawkins

Header image

Jim W Hawkins

Investment banker with GT Securities.
Dr. Hawkins, a bio sciences expert, raised equity and debt capital for many biotechnology companies including Synthecell Corporation and NeuroTrophic Bioscience Inc., a drug discovery company. He was instrumental in the acquisition of Vega Biotechnologies, Inc. and the sale of Genetic MediSyn Corp, an antisense technology company. Dr. Hawkins also served as CEO of Synthecell, Bio-Tech Imaging, Inc., a cell-based diagnostics company; SensorChem Corp., a scientific instrument company, Genetic MediSyn, and NeuroTrophic Bioscience Inc. Dr. Hawkins was also a Managing Director in Focus Investment Bankers where he developed Team strategy and helped direct transaction implementation. Dr. Hawkins co-founded and was former Editor-in-Chief of the peer-reviewed scientific journal Antisense Research and Development. He received his doctorate in molecular biology from Baylor College of Medicine in Houston, Texas. He conducted post-doctoral studies at the National Institutes of Health in Bethesda, Maryland, and served as a Full Professor and Director of the Biotechnology Program at Georgetown University. Dr. Hawkins also holds an MBA degree from George Mason University in Fairfax, Virginia.

Mr. Bish is a seasoned franchise executive, investor, and investment banker with over four decades of experience driving growth across the franchise industry. He has led strategic development for both emerging brands and established global concepts seeking U.S. market entry, with deep expertise in franchise development, operational scaling, and brand strategy.

His background includes leadership roles with concepts such as Pearle Vision, Banfield Pet Hospital, and AlphaGraphics. He has also founded a franchise software company, served in executive and board roles, and acted as a strategic advisor and consultant for over 22 years. In addition to his corporate roles, he has owned and successfully exited two franchise businesses.

Currently engaged with multiple companies in board and advisory capacities, Mr. Bish brings a cross-industry perspective that spans healthcare, fitness, consumer services, technology, and food & beverage. Known for his long-term approach to brand building, he specializes in aligning operational execution with growth-focused strategy to build lasting enterprise value.

‍

Dr. Hawkins, a bio sciences expert, raised equity and debt capital for many biotechnology companies including Synthecell Corporation and NeuroTrophic Bioscience Inc., a drug discovery company. He was instrumental in the acquisition of Vega Biotechnologies, Inc. and the sale of Genetic MediSyn Corp, an antisense technology company. Dr. Hawkins also served as CEO of Synthecell, Bio-Tech Imaging, Inc., a cell-based diagnostics company; SensorChem Corp., a scientific instrument company, Genetic MediSyn, and NeuroTrophic Bioscience Inc. Dr. Hawkins was also a Managing Director in Focus Investment Bankers where he developed Team strategy and helped direct transaction implementation. Dr. Hawkins co-founded and was former Editor-in-Chief of the peer-reviewed scientific journal Antisense Research and Development. He received his doctorate in molecular biology from Baylor College of Medicine in Houston, Texas. He conducted post-doctoral studies at the National Institutes of Health in Bethesda, Maryland, and served as a Full Professor and Director of the Biotechnology Program at Georgetown University. Dr. Hawkins also holds an MBA degree from George Mason University in Fairfax, Virginia.
Dr. Hawkins, a bio sciences expert, raised equity and debt capital for many biotechnology companies including Synthecell Corporation and NeuroTrophic Bioscience Inc., a drug discovery company. He was instrumental in the acquisition of Vega Biotechnologies, Inc. and the sale of Genetic MediSyn Corp, an antisense technology company. Dr. Hawkins also served as CEO of Synthecell, Bio-Tech Imaging, Inc., a cell-based diagnostics company; SensorChem Corp., a scientific instrument company, Genetic MediSyn, and NeuroTrophic Bioscience Inc. Dr. Hawkins was also a Managing Director in Focus Investment Bankers where he developed Team strategy and helped direct transaction implementation. Dr. Hawkins co-founded and was former Editor-in-Chief of the peer-reviewed scientific journal Antisense Research and Development. He received his doctorate in molecular biology from Baylor College of Medicine in Houston, Texas. He conducted post-doctoral studies at the National Institutes of Health in Bethesda, Maryland, and served as a Full Professor and Director of the Biotechnology Program at Georgetown University. Dr. Hawkins also holds an MBA degree from George Mason University in Fairfax, Virginia.
HomeMergers and AcquisitionsRaise CapitalConsultingOur TeamTransactions
Contact Us
info@hybridcapital.net
Securities are offered through Finalis Securities LLC Member FINRA / SIPC. Hybrid Capital is not a registered broker-dealer, and Finalis Securities LLC and Hybrid Capital are separate, unaffliated entities.

Finalis Privacy Policy | Finalis Business Continuity Plan | FINRA BrokerCheck
‍
www.hybridcapital.net (the Hybrid Capital Website) is a website operated by Hybrid Capital, a privately held Florida limited liability company. Hybrid Capital provides financial and strategic consulting services, mergers and acquisitions services, fairness opinions, etc.
‍
Disclaimer: This website is for informational purposes only, is not an offer, solicitation, recommendation, or commitment for any transaction or to buy or sell any security or other financial product, and is not intended as investment advice or as a confirmation of any transaction. Products and services on this website may not be available for residents of certain jurisdictions. Please consult with a Finalis Securities’ registered representative regarding the product or service in question for further information. Investments involve risk and are not guaranteed to appreciate. Any market price, indicative value, estimate, view, opinion, data, or other information herein is not warranted as to completeness or accuracy, is subject to change without notice, and Hybrid Capital along with Finalis Securities LLC accepts no liability for its use or to update it or keep it current.
Copyright © 2025 Hybrid Capital Consulting, LLC. All rights reserved.